# doctortb500.com # TB-500: Research Literature on the Thymosin Beta-4 Synthetic Fragment > TB-500 (Ac-LKKTETQ) has been studied in wound healing, tendon repair, cardiac protection, hair follicle activation, and neurological recovery across two decades of preclinical research. A cited literature digest. A botanical reading room for the peer-reviewed record on TB-500, the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4 — citing every quantitative claim. ## The short version TB-500 is a short synthetic peptide — seven amino acids, sequence Ac-LKKTETQ — taken from the actin-binding region of a protein your body already makes called Thymosin Beta-4. In animal studies, it has been looked at for wound healing, tendon and ligament repair, heart protection after injury, hair follicle activation, and neurological recovery. The parent protein has been tested in humans in two Phase I safety trials; the TB-500 fragment itself has not completed any controlled human trial for any condition. It is not FDA-approved. It is prohibited in competitive sport by WADA. The pages here gather what the peer-reviewed record actually says about each of those areas — with the species, doses, and limitations named plainly. For what people outside of research settings report experiencing, the [effects page](/effects) covers that separately. ## What Is the TB-500 Peptide? TB-500 is a synthetic heptapeptide — seven amino acids, sequence Ac-LKKTETQ — derived from residues 17 through 23 of Thymosin Beta-4, a 43-amino-acid endogenous signaling protein found in virtually every nucleated human cell. The acetylated N-terminus distinguishes TB-500 from the parent protein's native sequence. Molecular weight: 887 daltons. Thymosin Beta-4 itself was isolated from calf thymus in the early 1970s; its wound-healing properties were being characterized in rodent models by the late 1990s. The synthetic fragment designated TB-500 entered anti-doping literature in 2012, when Ho et al. validated an LC-MS/MS method for its detection in equine urine and plasma at detection limits of 0.01 ng/mL [12]. The research literature uses TB-500 and Thymosin Beta-4 (Tβ4) interchangeably in many contexts. This site covers both: findings on the full 43-amino-acid protein are noted where relevant; findings specifically on the 7-residue synthetic fragment are identified as such. The two are mechanistically related but not pharmacokinetically equivalent. In rodent wound models, Thymosin Beta-4 increased wound re-epithelialization by 42% at 4 days and 61% at 7 days post-wounding, with treated tissue contracting at least 11% more than controls and showing elevated collagen deposition and angiogenesis [2]. The active-region peptide — the sequence that TB-500 preserves — accelerated wound closure in both diabetic (db/db) and aged mice when applied topically [1]. These are the foundational observations that established the field. TB-500 is not FDA-approved for any human indication. It is a research compound. The Phase I human studies that exist in this literature evaluated full-length recombinant Thymosin Beta-4 — not the synthetic fragment — in intravenous administration contexts [9, 10]. That distinction matters and this site maintains it throughout. ## What Does TB-500 Do in Preclinical Studies? The primary mechanism is G-actin sequestration. TB-500 (and the full Thymosin Beta-4 protein) binds monomeric G-actin in a 1:1 stoichiometric ratio, modulating how much actin is available for cytoskeletal polymerization. That single interaction generates a cascade: cells become more motile, actin-based cytoskeletal rearrangements accelerate migration, and angiogenesis is upregulated via VEGFR2 signaling. The downstream effects documented in preclinical models include: - Wound closure and re-epithelialization acceleration [1, 2] - Medial collateral ligament repair with histologically and biomechanically improved collagen architecture [3] - Cardiac cardiomyocyte survival and improved post-infarct function via ILK/Akt activation [4, 5] - Hair follicle stem cell activation in the bulge region at nanomolar concentrations [6] - Myoblast chemotaxis following muscle injury [15] - Neuroprotective angiogenesis in rat traumatic brain injury models [8] - Anti-fibrotic activity in liver and cardiac tissue [5, 14] Across these findings, the consistent thread is cell migration. TB-500 promotes it in wound keratinocytes, ligament fibroblasts, cardiomyocytes, myoblasts, and hair follicle stem cells. Angiogenesis — new blood vessel formation via VEGFR2 — follows cell migration and is a secondary but critical effect in models where oxygen and nutrient delivery to injured tissue limits healing speed. For a detailed mechanism summary, see [TB-500 mechanism of action](/research#mechanism). ## Is TB-500 a Steroid? No. TB-500 is a synthetic peptide — a short amino acid chain. It shares no structural, mechanistic, or pharmacological class with anabolic steroids. Steroids are lipid-soluble molecules derived from cholesterol; they act on nuclear androgen, estrogen, or glucocorticoid receptors. TB-500 is a water-soluble heptapeptide; it acts on actin cytoskeletal dynamics and cell-surface signaling pathways. The confusion occasionally arises from the compound's association with performance-related research. TB-500 is classified by WADA under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) — the peptide category, not the anabolic steroid category — and is prohibited at all times as a non-Specified Substance carrying a maximum four-year sanction. ## What Does TB-500 Stand For? The TB-500 designation refers to Thymosin Beta-500 — a naming convention used in early peptide research and anti-doping contexts for the synthetic heptapeptide fragment corresponding to amino acids 17–23 of Thymosin Beta-4. The '500' element appeared in early peptide-synthesis literature to distinguish the fragment from the parent protein (Thymosin Beta-4, or TB4). In current research publications, the compound is more precisely identified by its sequence designation: N-acetyl-LKKTETQ, or Ac-LKKTETQ. The full research record — including its relationship to the parent protein and findings on both — is covered across this site. See the [frequently asked questions about TB-500](/faq) for more definitional context. ## The Research Record in Summary Twenty-one primary-source findings form the backbone of this literature digest. The strongest quantitative results: **Wound healing**: Thymosin Beta-4 at doses as low as 10 picograms increased wound re-epithelialization by 42% (day 4) and 61% (day 7) in rats; the active-fragment heptapeptide accelerated closure in diabetic and aged mouse models [1, 2]. **Ligament repair**: 1 µg of Thymosin Beta-4 administered via fibrin sealant to rat medial collateral ligament injury produced histologically uniform, biomechanically superior healing at 4 weeks compared to controls [3]. **Cardiac protection**: Two independent murine myocardial infarction studies showed cardiomyocyte survival improvement, reduced fibrosis, and improved cardiac function via ILK/Akt pathway activation and mitophagy promotion [4, 5]. **Hair follicles**: Nanomolar concentrations activated quiescent bulge-region hair follicle stem cells in rat and mouse models, stimulating keratinocyte migration and MMP-2 secretion [6]. **Human Phase I (full-length Tβ4)**: Two Phase I randomized trials — one in 40 healthy US volunteers (doses 42–1260 mg IV), one in 40 healthy Chinese volunteers — reported no dose-limiting toxicities, dose-proportional pharmacokinetics, and no accumulation on repeat dosing [9, 10]. **2024–2025 additions**: Zebrafish Mauthner axon regeneration via G-actin polymerization facilitation [19]; tandem tTB4 showing superior corneal wound healing over native TB4 [20]; Tβ4 attenuating NAFLD liver inflammation via M2 macrophage polarization at 12 mg/kg/day IP [21]. The full literature is organized in [TB-500 references and citations](/references). --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor. --- # TB-500 reported effects and safety: what the community says, what the research shows > TB-500 reported effects from research-use communities alongside the published safety cautions — benefits, adverse effects, and the honest limits of the evidence. Research context only. Community-reported effects from research-use contexts — plainly labeled as anecdotal — alongside the published safety cautions grounded in the preclinical and clinical literature. ## The short version TB-500 is a synthetic peptide studied in animal models for tissue repair, cardiac protection, and inflammation. People in research-use communities reach for it mainly hoping to recover faster from tendon, ligament and soft-tissue injuries. The peer-reviewed record for these effects is almost entirely in animals using the full parent protein, Thymosin Beta-4 — not the TB-500 fragment itself. The fragment has not completed any controlled human trial. What follows on this page is two separate layers: first, what people in those communities actually report experiencing (anecdotal, not clinical evidence); and second, the published safety cautions grounded in the literature. Neither layer is a recommendation. ## What people report **These are anecdotal reports gathered from research-use forums and community discussion — not clinical evidence. No human trial has tested TB-500 for any of these outcomes.** Frequency labels reflect how often a given effect appears in those discussions, not how likely it is in any individual. **Benefits reported** - *Faster recovery from tendon, ligament and muscle injuries* (very commonly reported) — The primary reason people in research-use communities reach for TB-500. Nagging soft-tissue injuries described as feeling better and allowing return to activity sooner than expected. Timelines vary widely. - *Less joint pain and stiffness; better range of motion* (frequently reported) — Joints described as looser and less achy after a few weeks. Most common in accounts of general wear-and-tear stiffness. - *Improved overall flexibility and mobility* (frequently reported) — Physical resilience during training, often noticed around three to four weeks in. - *Reduced inflammation or calmed-down soreness* (occasionally reported) — A vaguer sense of reduced swelling or post-workout soreness. Softer and less consistent than the injury-recovery signal. - *Better wound and skin healing* (occasionally reported) — Cuts or surgical sites described as closing more quickly. Not standardized. - *Hair regrowth or thicker hair* (rarely reported) — A minor, inconsistent signal in a smaller subset of accounts. **Adverse effects reported** - *Injection-site redness, swelling or aching* (very commonly reported) — The most common complaint, typically mild and gone within a day or two. - *Temporary tiredness or lethargy* (frequently reported) — Unusual tiredness for a day or two, especially early on. Reports say it fades with continued use. - *Head rush, lightheadedness or headache* (occasionally reported) — Brief and short-lived; tends to come up with larger early amounts. - *Brief flu-like feeling; nausea* (occasionally / rarely reported) — Mild, short-lived; more common at higher amounts. - *Heightened awareness of an existing injury; temporary mood changes* (rarely reported) — Vague and uncommon. No clinical evidence supports a mood mechanism. ## Safety and cautions The cautions below are drawn from the published literature. Theoretical cautions are identified as such. **Human safety is essentially unstudied.** There are no completed controlled human trials of the TB-500 heptapeptide for any use. A 2026 Sports Medicine narrative review of unapproved peptides — TB-500 among them — concluded that these compounds show promise in animal models but carry scarce human safety data, potential for serious harm, and operate largely outside regulatory oversight [22]. The only human data in this literature are Phase I safety trials of the full-length parent protein at intravenous doses up to 1260 mg, which reported mild, infrequent adverse events and no dose-limiting toxicities [9]. Those findings apply to the intact 43-amino-acid protein, not to the small fragment. **Theoretical cancer and tumor-growth concern.** People with a current or past cancer — or a strong family risk — are the group most consistently flagged for precaution. The parent protein Thymosin Beta-4 is overexpressed in several cancers and has been linked to tumor spread and to the formation of new blood vessels that feed tumors in preclinical models [23,24]. The same pro-migration and pro-angiogenic properties that may aid tissue repair could, in principle, also support tumor progression. This is a mechanistic concern derived from preclinical data, not a measured outcome in people using TB-500. **Banned in competitive sport.** Competitive and tested athletes should treat TB-500 as off-limits. It is prohibited by the World Anti-Doping Agency under its peptide and growth-factor categories. Anti-doping laboratories have validated detection methods in equine and human matrices, and a positive test can end an athlete's eligibility [12]. **Reported benefits may not reflect what the peptide actually does.** An honest animal study found the opposite of the community hype in one important case: in dystrophin-deficient mice, long-term Thymosin Beta-4 administration increased the number of regenerating muscle fibers but did NOT improve muscle strength, cardiac function, or fibrosis [16]. More regeneration markers on paper did not translate into better measured function — a caution against assuming that felt improvements mean real structural repair. **TB-500 is a fragment, not the full protein.** Almost all the encouraging efficacy research used full-length Thymosin Beta-4. TB-500 carries only residues 17–23, the actin-binding motif. Whether this short fragment reproduces the parent protein's full effects — or even its actin-binding potency at equivalent amounts — is not confirmed in peer-reviewed studies [12,13]. Claims often slide between the two without flagging the distinction. **Research-grade material quality is not guaranteed.** TB-500 sold for research use is not manufactured to pharmaceutical standards. Identity, purity, and sequence can vary between suppliers, a concern documented in analytical characterization work [25]. Unknown purity adds a separate, unpredictable risk on top of anything inherent to the peptide itself. **Theoretical cautions: clotting and surgery; pregnancy and development.** Because the parent protein influences blood-vessel formation and is released by platelets at injury sites, people approaching surgery or with clotting disorders may face uncertain effects — but no study has measured this for TB-500 in people. Similarly, because the compound acts on fundamental processes like cell migration and new vessel growth central to development, pregnancy, breastfeeding, and growing individuals represent a group where no human safety data exists and precautionary avoidance is the only defensible position. Both of these are mechanism-based extrapolations, not documented findings. --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor. --- # TB-500 Research: Mechanism, Tissue Repair Findings, and Clinical Context > TB-500 (Ac-LKKTETQ) binds G-actin, promotes cell migration, and upregulates VEGFR2-mediated angiogenesis. Detailed summaries of the preclinical and Phase I literature, with 21 cited findings. Organized findings from 21 primary sources — rodent wound and ligament models, murine cardiac studies, human Phase I pharmacokinetics, and the 2024–2025 literature. ## What the studies measure The TB-500 and Thymosin Beta-4 research record spans about three decades and covers several distinct tissue systems: skin and corneal wounds, tendon and ligament repair, the heart after a heart attack, hair follicle biology, brain injury recovery, and liver inflammation. Almost all of that work used the full 43-amino-acid Thymosin Beta-4 protein in animals — not the short TB-500 fragment. The two human Phase I trials tested intravenous Thymosin Beta-4 in healthy volunteers and found it well tolerated, but they were safety studies, not effectiveness studies. This page organizes the findings by mechanism and tissue type, naming the species and dose for each so the scope of the evidence is clear before any interpretation is drawn from it. ## TB-500 Mechanism of Action: Actin Binding and Cell Migration TB-500 (and its parent protein Thymosin Beta-4) binds monomeric G-actin in a 1:1 stoichiometric ratio. G-actin is the globular, monomeric form of actin — the pool from which cytoskeletal filaments (F-actin) are assembled. By sequestering G-actin, TB-500 modulates how rapidly cells can reorganize their internal scaffolding. The functional consequences of that sequestration are several: **Cell migration**: Cells that cannot efficiently polymerize actin cannot move. TB-500's G-actin binding keeps the cytoskeletal machinery in a dynamic state that promotes lamellipodial extension and directional migration. This has been demonstrated in keratinocytes, fibroblasts, myoblasts, endothelial cells, and hair follicle stem cells across multiple model systems [1, 2, 3, 6, 15]. **Angiogenesis via VEGFR2**: Endothelial cell migration is the rate-limiting step in new blood vessel formation. TB-500/Tβ4 upregulates VEGFR2 on endothelial cells, sensitizing them to vascular endothelial growth factor and accelerating capillary sprouting [17]. This VEGFR2-mediated angiogenic effect appears in wound models, cardiac ischemia models, and traumatic brain injury models [2, 4, 8]. **ILK/Akt activation**: In cardiomyocytes, Thymosin Beta-4 activates integrin-linked kinase (ILK), which in turn phosphorylates Akt/PKB — a survival signal that reduces apoptosis after ischemic injury [4]. This pathway is mechanistically distinct from the G-actin sequestration pathway and represents a second major mode of action in cardiac tissue. **Anti-inflammatory signaling**: Tβ4 upregulates microRNA-146a, a small non-coding RNA that suppresses Toll-like receptor pathway signaling and reduces pro-inflammatory cytokine production. In liver and NAFLD models, Tβ4 promotes macrophage M2 polarization — shifting immune cells from pro-inflammatory (M1) to anti-inflammatory, tissue-remodeling (M2) phenotype [21]. In cardiac models, AAV-delivered Tβ4 reduced IL-1β, IL-6, and TNF-α alongside promoting mitophagy [5]. **Myofibroblast suppression and anti-fibrosis**: Myofibroblasts are the cells responsible for scar formation. Thymosin Beta-4 suppresses myofibroblast differentiation and activity, reducing fibrosis in wound, cardiac, and liver models [13, 14]. In liver fibrosis models, Tβ4 blocked MAPK/NF-κB pathway activation by reducing ROS production and suppressed hepatic stellate cell migration and proliferation [14]. In the 2024 zebrafish study, TB-500/Tβ4 promoted axon regeneration in Mauthner neurons via the same G-actin binding and actin polymerization facilitation mechanism — with knockout impairing regeneration and overexpression restoring escape behavior functionality [19]. The N-terminal 13 amino acids were identified as essential for regenerative activity, a finding that has implications for fragment design. ## Thymosin Beta-4: The Endogenous Protein Behind TB-500 Thymosin Beta-4 (Tβ4) is a 43-amino-acid endogenous signaling peptide present in virtually every nucleated cell and at elevated concentrations in platelets, macrophages, and wound fluid. It is one of the most abundant intracellular peptides in eukaryotic cells, present at micromolar concentrations. TB-500 is a synthetic heptapeptide corresponding to residues 17–23 of Tβ4 — the actin-binding domain. The N-terminal acetylation in TB-500 (Ac-LKKTETQ) is artificial; it is not present in the native Tβ4 sequence. This acetylation is what makes TB-500 detectable separately from endogenous Tβ4 in anti-doping assays by LC-MS/MS [12]. The relationship between the two is one of fragment to parent. TB-500 preserves the actin-binding activity of Tβ4. It may not replicate all of Tβ4's biological functions — the full 43-residue protein has additional domains that mediate some of its cardiac, corneal, and neurological effects. The 2025 tandem tTB4 study illustrated this engineering tension: researchers fused two TB4 monomers to create dual G-actin binding domains, achieving superior corneal wound healing over both native TB4 and the fragment alone [20]. For the purpose of this reading room, findings on the full Tβ4 protein are included where they illuminate the biology and where the mechanisms are mediated through the actin-binding domain that TB-500 shares. Findings specific to the TB-500 fragment (primarily the equine anti-doping literature [12] and veterinary context) are labeled as such. ## TB-500 Benefits Observed in Preclinical Research Across two decades of preclinical research, the literature has documented the following effects of Thymosin Beta-4 and its TB-500 fragment in animal models and cell culture: **Wound re-epithelialization**: 42% increase at day 4, 61% at day 7 in rat wound models; accelerated closure in diabetic db/db and aged mice [1, 2]. **Ligament healing**: 1 µg administered via fibrin sealant to rat MCL injury produced biomechanically superior collagen with larger fibril diameters at 4 weeks vs. control [3]. **Cardiac cardiomyocyte protection**: ILK/Akt survival signaling reduced cardiomyocyte apoptosis after coronary artery ligation in mice [4]. AAV-Tβ4 attenuated cardiac inflammation (IL-1β, IL-6, TNF-α) and fibrosis via mitophagy promotion in a separate murine MI model [5]. **Hair follicle activation**: Nanomolar concentrations activated quiescent hair follicle stem cells in the bulge region, stimulating keratinocyte migration, differentiation, and MMP-2 secretion in rodent vibrissal follicle models [6]. **Muscle regeneration**: Tβ4 acted as a chemoattractant for C2C12 myoblasts after muscle injury; mRNA upregulation in early regenerating muscle fibers confirmed endogenous upregulation at injury sites [15]. Chronic 150 µg IP twice-weekly administration for 6 months increased regenerating fiber count in dystrophin-deficient mdx mice, though without measurable functional strength improvement in that model [16]. **Neurological recovery**: Tβ4 increased vascular density in injured cortex and hippocampus at 35 days post-TBI in rats, with neurological recovery attributed to angiogenesis and axonal remodeling [8]. **Axon regeneration (2024)**: Tβ4 promoted Mauthner axon regeneration in zebrafish via G-actin polymerization facilitation; overexpression restored escape behavior functionality [19]. **Dry eye (human Phase 2)**: RGN-259 (0.1% Tβ4 ophthalmic) produced a 35.1% reduction in ocular discomfort and 59.1% reduction in corneal fluorescein staining vs. vehicle at day 56 in a 9-patient Phase 2 trial [9 note: Sosne et al. 2015 is citation [9] in this table]. These benefits are documented in preclinical and limited human ophthalmic contexts. Translation to systemic human efficacy for tendon, cardiac, or muscle repair has not been demonstrated in published clinical trials for the TB-500 fragment or for full-length Tβ4 beyond the ophthalmic application. ## TB-500 Cardiac Research Two primary cardiac findings anchor the Thymosin Beta-4 cardiac literature: **Srivastava et al. 2007**: Thymosin Beta-4 administered to mice after coronary artery ligation upregulated ILK (integrin-linked kinase) and downstream Akt activity, enhanced early cardiomyocyte survival, and improved post-MI cardiac function [4]. This study established ILK/Akt activation as a primary cardioprotective mechanism. **Wang et al. 2022**: AAV-delivered Tβ4 (4 × 10¹⁰ viral genomes) in male C57BL/6 mice with myocardial infarction significantly reduced oxidative damage, attenuated cardiac inflammation (IL-1β, IL-6, TNF-α reduced), suppressed cardiac fibrosis, and improved cardiac function biomarkers [5]. The mechanism involved promotion of mitophagy — the selective removal of damaged mitochondria — as a means of reducing ROS-induced inflammasome activation. The angiogenic pathway is complementary to these survival findings. Thymosin Beta-4 promotes angiogenesis via VEGFR2 in ischemic cardiac tissue, potentially improving nutrient and oxygen supply to at-risk cardiomyocytes alongside the direct survival signaling [17]. No human cardiac efficacy trial for Thymosin Beta-4 or TB-500 has been published in the peer-reviewed literature. The compound has been reviewed as a candidate for cardiac ischemia research [18], and the human Phase I trials were positioned as safety studies preceding potential cardiac efficacy work [9, 10]. The gap between the murine findings and a human cardiac trial has not been bridged in published research as of this writing. ## TB-500 and Hair Follicle Research Thymosin Beta-4 increased hair growth by activating quiescent hair follicle stem cells in the bulge region of rodent vibrissal follicle models. Nanomolar concentrations stimulated clonogenic keratinocyte migration, differentiation, and MMP-2 secretion [6]. A related study confirmed that Tβ4 promotes hair follicle development alongside angiogenesis and wound healing in both normal and aged rodents — addressing the impaired angiogenesis and repair capacity associated with aging [7]. The TB-500 synthetic fragment (Ac-LKKTETQ) has not been independently validated for hair growth in peer-reviewed trials. The hair follicle findings are derived from the full Thymosin Beta-4 protein. Whether the 7-residue fragment preserves this activity is not established in peer-reviewed literature. ## TB-500 and BPC-157: Complementary Peptides in Recovery Research TB-500 and BPC-157 are the two most commonly co-discussed research peptides in the recovery biology literature. They are mechanistically distinct: **TB-500 (Tβ4 fragment)** — Primary mechanisms: G-actin sequestration, systemic VEGFR2-mediated angiogenesis, ILK/Akt cardiac survival signaling, macrophage M2 polarization, anti-fibrotic myofibroblast suppression. The mechanism is cytoskeletal and cell-migratory, operating broadly across tissue types. **BPC-157 (Body Protection Compound 157)** — Primary mechanisms: local VEGF upregulation, tendon fibroblast stimulation and collagen fiber organization, NO-mediated endothelial protection, GI mucosal protection, growth hormone receptor upregulation. The mechanism is angiogenic and fibroblastic, with particularly studied effects in GI and musculoskeletal tissue. The complementarity rationale — that TB-500's systemic actin-dynamics modulation pairs with BPC-157's local fibroblast and angiogenic effects — is mechanistically plausible based on the independent preclinical literature for each compound. No published peer-reviewed study has tested TB-500 and BPC-157 together in a controlled head-to-head design. The combination is referenced in community literature as the 'Wolverine stack' based on extrapolation. For TB-500 and BPC-157 combination: Safety Considerations, see the [TB-500 side effects](/side-effects#combination) page. The combination data gap is addressed in [frequently asked questions about TB-500](/faq). ## Recent Research: 2022–2025 The literature has added four substantial findings since 2022: **Wang et al. 2022 (cardiac fibrosis)**: AAV-Tβ4 significantly reduced oxidative damage, inflammation, cardiac dysfunction, and fibrosis in post-MI C57BL/6 mice. Mechanism: promotion of mitophagy and suppression of ROS-induced NLRP3 inflammasome activation [5]. **Wang Z et al. 2023 (liver fibrosis)**: Tβ4 blocked MAPK/NF-κB pathway activation in bile-duct-ligated mice by reducing ROS production. Overexpression suppressed hepatic stellate cell migration and proliferation; α-SMA and collagen markers reduced [14]. **Song et al. 2024 (axon regeneration)**: Tβ4 promoted zebrafish Mauthner neuron axon regeneration via G-actin polymerization facilitation. Knockout impaired regeneration; adenoviral overexpression restored escape behavior. N-terminal 13 amino acids identified as essential. Proposed as candidate for CNS repair drug development [19]. **Nguyen et al. 2025 (corneal engineering)**: Tandem tTB4 (two TB4 monomers fused for dual G-actin binding) showed superior corneal wound healing and reduced scarring vs. native TB4 in murine alkali-burn models. Practical synthesis via bacterial fermentation may reduce production costs [20]. **Zhu et al. 2025 (NAFLD)**: Tβ4 at 12 mg/kg/day IP attenuated NAFLD-associated inflammation in C57BL/6 mice via M2 macrophage polarization. Reduced TNF-α, IL-1β, iNOS; improved AST/ALT and oxidative stress markers [21]. The 2024–2025 additions extend the TB-500/Tβ4 literature into neurological axon regeneration and NAFLD inflammation — two tissue contexts not previously represented in the primary clinical-trial pipeline. --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor. --- # TB-500 Dosage in the Research Literature: Routes, Quantities, and Pharmacokinetics > TB-500 dosage in the research literature spans 1 µg local to 12 mg/kg systemic across animal models. Routes, quantities, frequency patterns, and human Phase I pharmacokinetics — research context only. Quantities and routes observed across animal models, in-vitro studies, and the two human Phase I pharmacokinetic trials of full-length Thymosin Beta-4. Research context only — no clinical recommendation is made or implied. ## Doses in the literature, plainly stated Published research has used Thymosin Beta-4 and TB-500 across a wide range of doses: from picogram amounts in cell culture assays, through microgram-per-kilogram doses in rodent injury models, up to gram-level intravenous doses in the human Phase I trials. These are research quantities in specific study designs — they are not validated human dosing recommendations, and no such recommendation exists for the TB-500 fragment. This page lists what each study actually used, the route, and what animal or human model it was tested in. It also covers what is known and not known about pharmacokinetics and why extrapolating animal doses to people is not supported by the published data. ## TB-500 Quantities Used in Research Protocols TB-500 dosage in published research spans an extremely wide range because the literature encompasses cell-culture assays (picogram concentrations), rodent in vivo models (microgram to milligram per kilogram), and human Phase I trials of the full-length protein (milligram to gram IV doses). The following table reflects documented research quantities — not clinical recommendations: | Study Context | Dose | Route | Model | |---|---|---|---| | Wound healing, migration assays (Malinda 1999) | 10 picograms (migration); topical | Topical, intraperitoneal | Rat | | Ligament healing (Xu 2013) | 1 µg | Local (fibrin sealant) | Rat MCL | | Hair follicle (Philp 2004) | Nanomolar | In vitro / in vivo | Rat, mouse | | Skeletal muscle, mdx mice (Spurney 2010) | 150 µg | Intraperitoneal, twice weekly × 6 months | Dystrophin-deficient mouse | | NAFLD liver inflammation (Zhu 2025) | 12 mg/kg/day | Intraperitoneal | Mouse | | Human Phase I (Ruff 2010) | 42, 140, 420, 1260 mg single dose; repeat dose × 14 days | Intravenous | 40 healthy volunteers | | Human Phase I Chinese volunteers (Wang 2021) | Multiple ascending doses | Not specified (recombinant) | 40 healthy volunteers | | Corneal dry eye Phase 2 (Sosne 2015) | 0.1% ophthalmic solution, 6×/day for 28 days | Topical ophthalmic | 9 human patients | Animal model dosing is not equivalent to human dosing. Allometric scaling from rodent to human requires body surface area or pharmacokinetic modeling adjustments — this has not been published in peer-reviewed literature for TB-500 specifically. This site describes research quantities only. 'How much TB-500 should I take?' is not a question this literature digest answers — that framing is not appropriate for a research compound without validated human pharmacokinetics. ## TB-500 Dosing Frequency in the Literature Preclinical administration schedules vary substantially by model and endpoint: - Single-dose or short-course protocols appear in wound closure models (days to 2 weeks) - Chronic protocols appear in muscle degeneration models: Spurney et al. (2010) administered 150 µg IP twice weekly for 6 months in mdx mice [16] - Daily intraperitoneal administration appears in the NAFLD liver inflammation model at 12 mg/kg/day [21] - The human Phase I trial by Ruff et al. (2010) evaluated 14-day daily IV dosing alongside single-dose ascending cohorts [9] No validated human dosing frequency schedule exists for TB-500 or for Thymosin Beta-4 in musculoskeletal, cardiac, or neurological indications. The ophthalmic dry eye protocol (6× daily topical for 28 days) is disease-specific and was for a 0.1% Tβ4 eye drop formulation — not a systemic peptide [8]. Anecdotal community literature describes 2–3× weekly protocols. These are not derived from controlled clinical research. ## TB-500 Half-Life and Clearance in Animal Models Formal pharmacokinetic data for TB-500 (the 7-residue Ac-LKKTETQ fragment) in humans is absent from the peer-reviewed literature. The anti-doping detection methodology study by Ho et al. (2012) validated LC-MS/MS detection of TB-500 in equine urine and plasma at limits of 0.01 ng/mL and 0.02 ng/mL respectively, but did not characterize a plasma half-life [12]. For full-length Thymosin Beta-4 (Tβ4), the Phase I IV pharmacokinetic trial by Ruff et al. (2010) confirmed dose-proportional Cmax and AUC across doses of 42–1260 mg, with increasing half-life at higher IV doses — but specific half-life values were not published in the available abstract [9]. The Chinese Phase I study by Wang et al. (2021) similarly confirmed consistent terminal clearance across dose groups without accumulation on repeat dosing [10]. The practical implication: the published human pharmacokinetic data is for the 43-amino-acid protein administered intravenously at gram-range doses in a controlled research context. Extrapolating these values to the 7-residue synthetic fragment administered by other routes is not supported by published evidence. The stability note in the research context: TB-500 as a lyophilized synthetic peptide is stable in powder form. Research preparations are reconstituted in bacteriostatic water or sterile saline for injectable use in animal models. Short peptide half-life has been cited as a limitation driving the engineered tandem tTB4 analog (Nguyen et al. 2025) with dual G-actin binding domains [20]. ## Routes of Administration in Preclinical Research Research models have employed several administration routes: **Intraperitoneal (IP)**: The most common preclinical route in rodent models. Used in the skeletal muscle study (150 µg, mdx mice) [16], the NAFLD study (12 mg/kg/day) [21], and cardiac AAV delivery contexts [5]. **Topical**: Used in wound healing and corneal studies. The original wound re-epithelialization findings in rats used both topical and intraperitoneal administration [2]. The dry eye Phase 2 used 0.1% ophthalmic drops, 6× daily [8]. **Local/intralesional**: The medial collateral ligament study delivered Tβ4 via fibrin sealant placed directly in the ligament gap at 1 µg — a highly localized approach without systemic exposure [3]. **Intravenous**: The two human Phase I trials of full-length Tβ4 used IV administration. This is the only peer-reviewed route with human pharmacokinetic data [9, 10]. **Subcutaneous**: The equine anti-doping literature identifies subcutaneous administration as the veterinary route; the detection methodology was validated in post-SC-administration samples [12]. Oral bioavailability of TB-500 has not been established in peer-reviewed studies. Oral peptide delivery faces proteolytic degradation in the GI tract — stomach acid and digestive enzymes cleave short peptide sequences efficiently. No peer-reviewed pharmacokinetic study has demonstrated meaningful oral bioavailability for TB-500 or Thymosin Beta-4. ## Oral vs. Injectable Administration in Research Most preclinical research administers TB-500/Tβ4 via subcutaneous, intramuscular, intraperitoneal, topical, or intravenous injection. Oral delivery of peptides is challenging: the GI tract's proteolytic environment degrades small peptide sequences before they reach systemic circulation at meaningful concentrations. No peer-reviewed study has demonstrated oral bioavailability of TB-500 (Ac-LKKTETQ) in any species. Community discussion of oral TB-500 exists, but the pharmacokinetic rationale for oral absorption of a 7-amino-acid acetylated peptide at biologically relevant concentrations is not supported by published data. The 2025 tandem tTB4 (Nguyen et al.) study addressed production efficiency via bacterial fermentation synthesis — a cost concern, not a bioavailability improvement. The compound in that study was administered topically to the cornea [20]. ## Reconstitution in Research Settings The research literature describes reconstitution of lyophilized TB-500 and Tβ4 preparations in bacteriostatic water or sterile saline for injectable use in animal model research. Stability and optimal concentration vary by study protocol; no standardized clinical reconstitution guideline exists for the compound. In anti-doping reference sample preparation (Ho et al. 2012), the compound was reconstituted for standard preparation in equine plasma and urine matrices for assay validation purposes [12]. This is descriptive of research laboratory practice. It is not a preparation instruction. ## Onset of Effect in Preclinical Models Animal studies report measurable tissue-repair markers within days to weeks, depending on the injury model and endpoint: - Wound re-epithelialization: 42% improvement measured at day 4, 61% at day 7 in rat wound models [2] - Ligament healing: histological and biomechanical improvement at 4 weeks vs. controls [3] - Cardiac recovery: vascular and functional markers assessed at post-infarct intervals ranging from days (acute survival) to weeks (fibrosis outcomes) [4, 5] - Neurological (TBI): vascular density improvement measured at 35 days post-injury [8] These are model-specific endpoints. No validated human onset data exists for TB-500 or for systemic Tβ4 in musculoskeletal, cardiac, or neurological indications. ## TB-500 Clearance and Systemic Persistence No peer-reviewed human pharmacokinetic data for TB-500 (Ac-LKKTETQ) specifically. For full-length Thymosin Beta-4, human Phase I IV data confirmed dose-proportional pharmacokinetics with no accumulation on 14-day repeat dosing at 42–1260 mg doses [9, 10]. Specific half-life values were not published in available abstracts. Detection windows for TB-500 in anti-doping contexts have been partially characterized in equine samples via LC-MS/MS (detection limits 0.01 ng/mL urine, 0.02 ng/mL plasma) [12], but human detection window data has not been published in peer-reviewed literature. At least one athlete has received a sanction from the Canadian Centre for Ethics in Sport for TB-500 use, indicating practical detection capability in human samples — but the underlying detection methodology for human samples is not publicly documented in peer-reviewed form. --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor. --- # TB-500 Side Effects: What the Research Shows on Safety and Tolerability > TB-500 side effects in the published literature: animal model tolerability, human Phase I adverse event profiles for full-length Tβ4, WADA classification, and the data gap for the synthetic fragment. Animal tolerability data, human Phase I adverse event profiles for full-length Thymosin Beta-4, WADA classification, and the limits of the current safety evidence base for the synthetic fragment. ## TB-500 Safety Profile in Research TB-500 side effects in the peer-reviewed literature are primarily characterized through two bodies of evidence: animal model tolerability data and human Phase I adverse event reporting for full-length Thymosin Beta-4 (Tβ4). The synthetic fragment TB-500 (Ac-LKKTETQ) itself has no published human safety trial. In preclinical rodent studies across wound healing, ligament, cardiac, and muscle models, Thymosin Beta-4 is generally reported as well tolerated. The chronic administration study by Spurney et al. (2010) — 150 µg IP twice weekly for 6 months in dystrophin-deficient mdx mice — noted no overt toxicity signals, though it also found no functional strength improvement [16]. For full-length Tβ4 in humans: **Ruff et al. 2010**: In 40 healthy volunteers, intravenous single doses of 42, 140, 420, and 1260 mg produced adverse events that were infrequent and mild or moderate in intensity. No dose-limiting toxicities. No serious adverse events. Compound was considered acceptable for further cardiac ischemia studies [9]. **Wang et al. 2021**: In 40 healthy Chinese volunteers receiving multiple ascending doses, full-length recombinant Tβ4 was safe and well tolerated with no dose-limiting toxicities, dose-proportional pharmacokinetics, and no accumulation on repeat dosing [10]. **Sosne et al. 2015 (Phase 2 ophthalmic)**: RGN-259 (0.1% Tβ4 topical ophthalmic) produced no serious adverse events in 9 patients over 28 days [8]. The gap: none of these trials characterized the safety of the TB-500 synthetic fragment (Ac-LKKTETQ) specifically. Extrapolating from the full Tβ4 safety data to the 7-residue fragment is plausible given the fragment's smaller size and simpler structure, but it is not validated. ## Reported Side Effects of TB-500 In animal studies, TB-500 and Tβ4 are generally well-tolerated at the doses studied. No significant organ toxicity was reported across wound, ligament, cardiac, or muscle models in the available peer-reviewed literature. Anecdotal adverse events reported in human community contexts include: - Injection-site reactions (redness, swelling, mild pain at the injection site) - Temporary fatigue following administration - Mild dizziness or lightheadedness These observations come from anecdotal reports, not controlled safety studies. They are noted here because they are the most commonly described human-context adverse events in the community literature; they are not documented in peer-reviewed clinical trials of the TB-500 fragment itself. Long-term human safety data for TB-500 does not exist in peer-reviewed form. The Phase I trials for full-length Tβ4 were short-term (14-day dosing periods) and used small samples (40 subjects each) — they do not characterize chronic safety. ## TB-500 and BPC-157 Combination: Safety Considerations No formal human safety study exists for the TB-500 + BPC-157 combination. The combination has not been tested in a controlled animal study published in indexed peer-reviewed literature either. Anecdotal reports in community contexts cite adverse events similar to those reported for each compound individually — injection-site reactions and fatigue being the most common — without documented additive or synergistic toxicity in the available literature. The theoretical mechanistic overlap (both compounds affect angiogenic and tissue repair pathways) raises no obvious pharmacodynamic toxicity concern based on the independent preclinical data, but this is extrapolation, not evidence. This literature digest covers what is published. For the TB-500 and BPC-157 combination, the honest position is: the combination clinical data does not exist. ## General Peptide Safety Considerations Research peptides as a class carry risks that apply broadly, regardless of the compound's individual safety profile: **Purity**: Unregulated commercial sources produce research peptides without the quality controls required for pharmaceutical manufacturing. Contaminants, bacterial endotoxins, peptide impurities, and incorrect sequences have been documented in the research-peptide market. These are manufacturing risks, not pharmacological risks inherent to the compound. **Injection-site risk**: Any injectable compound carries inherent injection-site infection risk if sterile technique is not maintained. **Unknown long-term effects**: No long-term human safety data exists for TB-500 or the synthetic fragment specifically. Short-term Phase I trials with small samples are not sufficient to characterize rare or delayed adverse events. **Immune response**: Exogenous peptides can trigger immune responses, including anti-peptide antibody formation. This has not been reported as a problem in the Tβ4 Phase I trials, but it is a theoretical concern for repeat administration. **WADA classification**: TB-500 is prohibited at all times under WADA S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and S0 (Non-Approved Substances). It is a non-Specified Substance carrying a maximum 4-year sanction. Competitive athletes face serious career consequences. ## Is TB-500 Safe? The honest research-based answer: animal studies report favorable tolerability; human safety data is limited to short-term Phase I trials of the full-length Tβ4 protein, which showed mostly mild, transient adverse events at doses up to 1260 mg IV in 40-person cohorts [9, 10]. TB-500 (the 7-residue fragment) has no published human safety trial. What is not known: long-term effects, effects at doses outside the Phase I trial ranges, the specific safety profile of the synthetic fragment (vs. the full protein), and the safety of chronic administration in the diverse health contexts where the compound is used outside of research. The data supports cautious characterization as 'apparently tolerated in controlled animal studies and in human Phase I trials of the full protein.' It does not support characterization as 'proven safe' in a clinical sense. ## Is TB-500 FDA Approved? TB-500 is not FDA-approved for any human indication. It is studied as a research compound only. Full-length Thymosin Beta-4 (the parent protein) has been investigated in human clinical trials: Phase I safety studies in healthy volunteers [9, 10] and a Phase 2 ophthalmic trial for severe dry eye disease (Sosne et al. 2015) [8]. As of 2025, no FDA-approved product containing TB-500 or Thymosin Beta-4 for systemic human use has been authorized. RGN-259 (Tβ4 ophthalmic) completed Phase 2 trials but has not received FDA approval for dry eye disease as of this writing. TB-500 is not classified as a controlled substance. It occupies a research-chemical status — legally complex, not pharmacologically categorized under the Controlled Substances Act. ## Research Context and Cautions Clinical commentary has noted that individuals with active malignancy, autoimmune conditions, or during pregnancy represent populations warranting particular caution — since Tβ4's pro-angiogenic and cell-migration-promoting effects are theoretically relevant in contexts where angiogenesis and cell proliferation are already dysregulated. These are not formal contraindications established by clinical trial data; they are theoretical cautions derived from mechanistic extrapolation. This reading room does not provide medical guidance. The above mechanistic observations are drawn from the peer-reviewed literature and are offered as context for understanding the research discussions — not as clinical advice. --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor. --- # TB-500 FAQ: Questions from the Research Community, Answered from the Literature > TB-500 frequently asked questions — what it is, how it works, dosage context, side effects, comparison with BPC-157, WADA status, and the limits of the current evidence base. Cited from published studies. Twenty-five questions drawn from keyword research and community discussion, answered directly from the peer-reviewed literature and the limits of what it shows. ## Definitions and Basics ### What is TB-500? TB-500 is a synthetic heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17–23 of Thymosin Beta-4, an endogenous signaling protein studied for its role in actin regulation, cell migration, and tissue repair in preclinical models. The acetylated N-terminus distinguishes it from the native TB4 sequence. Molecular weight: 887 daltons. ### What does TB-500 stand for? TB-500 refers to Thymosin Beta-500 — a naming convention used in research and anti-doping contexts for the synthetic heptapeptide fragment corresponding to residues 17–23 of Thymosin Beta-4. The '500' designation appeared in early peptide synthesis literature to distinguish the fragment from the parent protein. In current research it is more precisely labeled Ac-LKKTETQ or N-acetyl-LKKTETQ. ### What is the relationship between TB-500 and Thymosin Beta-4? Thymosin Beta-4 (Tβ4) is the full endogenous 43-amino-acid protein. TB-500 is a synthetic 7-amino-acid fragment corresponding to its actin-binding region (residues 17–23). TB-500 preserves the G-actin sequestration activity of Tβ4 but may not replicate all of the parent protein's biological effects. The full protein has been studied in human clinical trials; the fragment has not. The two are mechanistically related but not pharmacokinetically equivalent. ### Is TB-500 a steroid? No. TB-500 is a synthetic peptide — a short amino acid chain. It is structurally and mechanistically distinct from anabolic steroids, which are lipid-soluble cholesterol derivatives acting on nuclear receptors. TB-500 acts on G-actin cytoskeletal dynamics and VEGFR2-mediated cell-surface signaling. WADA classifies it under S2 (Peptide Hormones, Growth Factors, Related Substances) — the peptide category. ### What peptides does TB-500 combine with in research stacks? TB-500 is most commonly co-discussed with BPC-157 in what researchers and community literature label the 'Wolverine stack' — hypothesized to combine BPC-157's GI-protective and tendon-fibroblast-specific effects with TB-500's systemic angiogenic and anti-fibrotic properties. No published peer-reviewed study has tested the two together in a controlled design. All combination claims derive from extrapolation from each compound's independent preclinical literature. ## Mechanism and Effects ### How does TB-500 work? TB-500 binds monomeric G-actin in a 1:1 stoichiometric ratio, sequestering it and modulating cytoskeletal dynamics. This promotes cell motility and migration, upregulates VEGFR2-mediated angiogenesis, reduces inflammation via microRNA-146a upregulation and macrophage M2 polarization, and activates ILK/Akt survival signaling in cardiomyocytes. Multiple downstream effects emerge from that single actin-binding interaction. ### What is TB-500 used for in research? Preclinical research has examined TB-500 and Thymosin Beta-4 in models of wound closure [1, 2], tendon and ligament repair [3], cardiac tissue regeneration post-infarction [4, 5], hair follicle stem cell activation [6], traumatic brain injury [8], axon regeneration [19], and liver inflammation and fibrosis [14, 21]. No FDA-approved human indication exists for the compound. ### What is the benefit of BPC-157 and TB-500 together? Researchers have studied BPC-157 and TB-500 as mechanistically complementary: BPC-157 is associated with GI protection, tendon fibroblast activity, and local angiogenesis; TB-500 is studied for systemic actin-cytoskeletal modulation, VEGFR2-mediated angiogenesis, and anti-fibrotic effects. The hypothesized complementarity is mechanistically plausible based on each compound's independent preclinical record. Combined protocols appear in anecdotal literature; head-to-head human trials are absent. ### Does TB-500 increase hair growth? Thymosin Beta-4 activated quiescent hair follicle stem cells in the bulge region at nanomolar concentrations in rodent vibrissal follicle models, stimulating keratinocyte migration, differentiation, and MMP-2 secretion [6]. TB-500 (the synthetic 7-residue fragment) has not been independently validated for hair growth in peer-reviewed trials. The hair follicle findings come from full-length Tβ4 studies. ### Is TB-500 good for the heart? Thymosin Beta-4 has been studied in murine myocardial infarction models, where ILK/Akt pathway activation promoted cardiomyocyte survival [4] and AAV-delivered Tβ4 reduced cardiac inflammation and fibrosis via mitophagy promotion [5]. These are preclinical findings in mice. No human cardiac efficacy trial for Tβ4 or TB-500 has been published in peer-reviewed literature. ### Does TB-500 help the heart? Preclinical cardiac models (primarily murine) show Thymosin Beta-4 promotes angiogenesis and reduces cardiomyocyte apoptosis post-injury via ILK/Akt signaling. Two independent murine MI studies confirmed cardiac protective effects [4, 5]. Human cardiac efficacy evidence is absent from the published literature. ### Does TB-500 only work for physical injury or can it help with systemic inflammation? The research literature extends beyond musculoskeletal injury. Tβ4 has been studied for anti-inflammatory effects in cardiac tissue [5], liver fibrosis [14], NAFLD [21], and traumatic brain injury [8]. The mechanism — macrophage M2 polarization, MAPK/NF-κB pathway suppression, miR-146a upregulation — is systemic rather than tissue-specific. Whether the 7-residue TB-500 fragment reproduces systemic anti-inflammatory effects observed with the full Tβ4 protein has not been validated in published studies. ## Dosage and Administration ### How much TB-500 should I take? This reading room describes research quantities used in published animal studies — not clinical recommendations. Preclinical animal studies use weight-based dosing ranging from 1 µg local (rat ligament) [3] to 12 mg/kg/day IP (mouse liver model) [21]. Extrapolation to humans is not validated. This is research context only. ### Can TB-500 be taken every day? Preclinical protocols vary. Some animal studies use daily administration (the NAFLD model at 12 mg/kg/day [21]); others use 2–3× weekly (Spurney et al. 2010, twice weekly × 6 months in mdx mice [16]). The human Phase I IV trial used daily dosing over 14 days for the repeat-dose cohort [9]. No validated human dosing schedule exists for musculoskeletal or systemic indications. ### How quickly does TB-500 work? Animal studies report measurable tissue-repair markers within days to weeks, depending on the model: wound re-epithelialization improvements were measured at day 4 and day 7 [2]; ligament histological improvements at 4 weeks [3]; neurological TBI improvements at 35 days [8]. No validated human onset data is available. ### How long does TB-500 stay in your system? No peer-reviewed human pharmacokinetic data for TB-500 (Ac-LKKTETQ) specifically. For full-length Tβ4, human Phase I IV data confirmed dose-proportional pharmacokinetics with no accumulation on 14-day repeat dosing [9, 10]. Specific half-life values were not published in available abstracts. Detection windows in anti-doping contexts have been partially characterized in equine samples by LC-MS/MS [12], but human detection window data has not been published in peer-reviewed form. ### Can TB-500 be taken orally? Most preclinical research administers TB-500/Tβ4 via subcutaneous, intraperitoneal, local/intralesional, or intravenous routes. Oral peptide delivery faces proteolytic degradation in the GI tract. Oral bioavailability of TB-500 has not been established in peer-reviewed studies in any species. Community-context oral administration anecdotes exist but are not supported by published pharmacokinetic evidence. ### Where to inject TB-500? Animal studies employ subcutaneous and intramuscular injection routes in rodent models. Intravenous and intraperitoneal routes appear in some rodent and human Phase I protocols. The anti-doping equine literature identifies subcutaneous as the route for which detection methodology was validated [12]. Injection-site preference in community research contexts is anecdotal and not addressed in the clinical literature. ### How to reconstitute TB-500? Research laboratory preparations of Tβ4 and TB-500 for animal studies use bacteriostatic water or sterile saline as the diluent for injectable preparations. Stability and concentration vary by study protocol; no standardized clinical reconstitution guideline exists. This reflects research practice, not a preparation instruction. ### Do you NEED to keep dosing TB-500 to maintain results? The published literature does not address maintenance dosing in the context of this question. The chronic mdx mouse study (Spurney 2010) administered twice-weekly IP for 6 months and showed increased regenerating fiber count; no follow-up data characterized what happened post-cessation [16]. For wound healing studies, treatment periods were short-course and endpoint measurement was at defined time points. Maintenance dosing claims in community contexts are not derived from controlled clinical evidence. ## Safety and Regulatory ### What are the side effects of TB-500? In animal studies, TB-500 and Tβ4 are generally well-tolerated. Human Phase I trials of full-length Tβ4 reported infrequent, mild-to-moderate adverse events with no dose-limiting toxicities at IV doses up to 1260 mg in 40 volunteers [9, 10]. Anecdotal adverse events in human community contexts include injection-site reactions, temporary fatigue, and mild dizziness. Long-term human safety data for the synthetic TB-500 fragment does not exist in peer-reviewed form. ### What are the side effects of TB-500 combined with BPC-157? No formal human safety studies exist for the TB-500 + BPC-157 combination, and no controlled animal study of the combination has been published in indexed literature. Anecdotal reports cite similar individual adverse events — injection-site reactions and fatigue — without documented additive toxicity in the available literature. The combination data gap is real. ### What are the bad side effects of taking peptides? Research peptides carry risks including injection-site reactions, immune responses to exogenous protein sequences, unknown long-term effects, and purity concerns from unregulated commercial sources. TB-500 has not been approved by the FDA for human use. Any injectable compound used outside a controlled medical setting carries inherent infection risk from non-sterile technique. ### Who should avoid peptides? Clinical commentary notes that individuals with active malignancy, autoimmune conditions, or during pregnancy warrant particular caution — Tβ4's pro-angiogenic and cell-migration-promoting mechanisms are theoretically relevant in contexts where those processes are already dysregulated. These are not formal contraindications established by clinical trial data; they are mechanistic extrapolations from the preclinical literature. This site does not provide clinical guidance. ### Is TB-500 safe? Animal studies report favorable tolerability. Human safety data is limited to short-term Phase I trials of the full-length Tβ4 protein, which showed mostly mild, transient adverse events at IV doses up to 1260 mg in 40-person cohorts [9, 10]. TB-500 (the 7-residue synthetic fragment) has no published human safety trial. Long-term effects are unknown. The data supports 'apparently tolerated in controlled animal studies and in human Phase I trials of the full protein' — not 'proven safe.' ### Is TB-500 FDA approved? TB-500 is not FDA-approved for any human indication. It is studied as a research compound only. Full-length recombinant Tβ4 has been studied in Phase I and Phase 2 human trials with favorable tolerability in specific contexts [9, 10], but no FDA-approved product containing TB-500 or Tβ4 for systemic human use exists as of 2025. TB-500 is not a controlled substance under the Controlled Substances Act. --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor. --- # TB-500 References: Cited Research Literature and Primary Sources > Complete bibliography of the 21 peer-reviewed studies and reviews cited across DoctorTB500.com — PubMed links, DOIs, and full citation details for every TB-500 and Thymosin Beta-4 finding referenced on this site. Every quantitative claim on this site traces to a numbered citation below. Twenty-one primary sources and reviews — PubMed links and DOIs included. ## Primary Sources The full citation list for all TB-500 and Thymosin Beta-4 research summarized on this site. Citations are numbered as they appear in body text throughout the site. All citations verified against PubMed, PMC, or journal DOI at time of publication. See the [TB-500 references and citations](/references) page for the indexed list. ## References [1] Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. https://pubmed.ncbi.nlm.nih.gov/12581423/ [2] Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/ [3] Xu B, Yang M, Li Z, Zhang Y, Jiang Z, Guan S, Jiang D. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013;184:1-5. https://pubmed.ncbi.nlm.nih.gov/23523891/ [4] Srivastava D, Saxena A, Dimaio JM, Bock-Marquette I. Thymosin beta4 is cardioprotective after myocardial infarction. Ann N Y Acad Sci. 2007;1112:171-177. https://pubmed.ncbi.nlm.nih.gov/17600280/ [5] Wang F, He Y, Yao N, Ruan L, Tian Z. Thymosin β4 Protects against Cardiac Damage and Subsequent Cardiac Fibrosis in Mice with Myocardial Infarction. Cardiovasc Ther. 2022;2022:1308651. https://pmc.ncbi.nlm.nih.gov/articles/PMC9187458/ [6] Philp D, Nguyen M, Scheremeta B, St-Surin S, Villa AM, Orgel A, Kleinman HK, Elkin M. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004;18(2):385-387. https://pubmed.ncbi.nlm.nih.gov/14657002/ [7] Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. https://pubmed.ncbi.nlm.nih.gov/15037013/ [8] Xiong Y, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, Chopp M. Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. Ann N Y Acad Sci. 2012;1270:51-58. https://pubmed.ncbi.nlm.nih.gov/23050817/ [9] Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. https://pubmed.ncbi.nlm.nih.gov/20536472/ [10] Wang X, Liu L, Qi L, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8439-8447. https://pmc.ncbi.nlm.nih.gov/articles/PMC8419156/ [11] Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. https://pubmed.ncbi.nlm.nih.gov/25826322/ [12] Ho EN, Kwok WH, Lau MY, Wong AS, Wan TS, Lam KK, Schiff PJ, Stewart BD. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. https://pubmed.ncbi.nlm.nih.gov/23084823/ [13] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/ [14] Wang Z, Zhang Y, Wang Y, Mou Q, Ren T, Zhu L. Mechanism of thymosin β4 in ameliorating liver fibrosis via the MAPK/NF-κB pathway. J Biochem Mol Toxicol. 2023;37(8):e23338. https://pubmed.ncbi.nlm.nih.gov/37211724/ [15] Tokura Y, Nakayama Y, Fukada S, Nara N, Yamamoto H, Matsuda R, Hara T. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts. J Biochem. 2011;149(1):43-48. https://pubmed.ncbi.nlm.nih.gov/20880960/ [16] Spurney CF, Cha HJ, Sali A, et al. Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse. PLoS One. 2010;5(1):e8976. https://pmc.ncbi.nlm.nih.gov/articles/PMC2813286/ [17] Smart N, Rossdeutsch A, Riley PR. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Angiogenesis. 2007;10(4):229-241. https://pubmed.ncbi.nlm.nih.gov/17632766/ [18] Goldstein AL, Kleinman HK. Advances in the basic and clinical applications of thymosin β4. Expert Opin Biol Ther. 2015;15(sup1):137-145. https://pubmed.ncbi.nlm.nih.gov/26096726/ [19] Song Z, Han A, Hu B. Thymosin β4 promotes zebrafish Mauthner axon regeneration by facilitating actin polymerization through binding to G-actin. BMC Biol. 2024;22(1):239. https://pmc.ncbi.nlm.nih.gov/articles/PMC11515629/ [20] Nguyen J, Verma S, Vuong VT, Queener H, Coulson-Thomas VJ, Gesteira TF. Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. Invest Ophthalmol Vis Sci. 2025;66(14):31. https://pubmed.ncbi.nlm.nih.gov/41235866/ [21] Zhu Z, Liao Y, Mou Q, Liu H, Shen Y, Zhu L, Cong S. Thymosin β4 Regulates Tissue Inflammatory Response in Mouse Nonalcoholic Fatty Liver Disease by Promoting Macrophage M2-Type Polarization. J Inflamm Res. 2025;18:5641-5655. https://pmc.ncbi.nlm.nih.gov/articles/PMC12049133/ [22] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(7):1583-1600. https://pubmed.ncbi.nlm.nih.gov/41966639/ [23] Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003;95(22):1674-1680. https://pubmed.ncbi.nlm.nih.gov/14625258/ [24] Wang WS, Chen PM, Hsiao HL, Wang HS, Liang WY, Su Y. Thymosin beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther. 2008;7(3):454-460. https://pubmed.ncbi.nlm.nih.gov/18094619/ [25] Thomas A, Coppens P, Thevis M. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of doping-relevant peptide preparations. Drug Test Anal. 2023;15(7):746-754. https://pubmed.ncbi.nlm.nih.gov/36482504/ --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor. --- # About Doctor TB-500: An Independent Editorial Reading Room for the TB-500 Literature > Doctor TB-500 is an independent editorial project that publishes plain-language summaries of the peer-reviewed research on TB-500 and Thymosin Beta-4. Not a clinic, not a vendor. An independent editorial project and reading room for the TB-500 and Thymosin Beta-4 research literature. ## What This Site Is Doctor TB-500 is an independent editorial project that publishes summaries of the peer-reviewed research literature on TB-500 and its parent protein, Thymosin Beta-4. The research record on this compound spans wound healing, tendon and ligament repair, cardiac protection, hair follicle biology, traumatic brain injury, neurological axon regeneration, and two human Phase I pharmacokinetic trials — a genuinely heterogeneous literature that rewards a reading room. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The 'Doctor' in the name is editorial framing — a position this publication occupies relative to the research literature, as a careful reader, organizer, and summarizer of published findings. It is not a claim about clinical services, medical staff, or treatment capabilities. This site does not offer treatment, consultation, or prescription services of any kind. Every quantitative claim on this site traces to a numbered citation in the references index. Findings are described at the dose, route, species, and outcome level documented in the source study. Where the evidence is limited, this site says so. ## Regulatory Status of TB-500 TB-500 is not FDA-approved for any human indication. It is studied as a research compound only. Full-length Thymosin Beta-4 has been investigated in Phase I human trials and in a Phase 2 ophthalmic trial; as of 2025, no FDA approval exists for systemic Tβ4 or for the TB-500 synthetic fragment in any indication. TB-500 is listed on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and is also captured by S0 (Non-Approved Substances). It is prohibited at all times — in-competition and out-of-competition — and classified as a non-Specified Substance carrying the maximum four-year sanction. At least one athlete has been sanctioned by the Canadian Centre for Ethics in Sport for TB-500 use. TB-500 is not classified as a controlled substance under the US Controlled Substances Act. This regulatory context is described accurately and without advocacy in either direction. It is part of the research record. ## Editorial Standards This site follows a strict citation policy: every quantitative claim maps to a specific numbered citation in the references list. Citations are drawn from PubMed-indexed journals, PubMed Central, ClinicalTrials.gov, and peer-reviewed reviews. Where a claim is derived from a review article rather than primary research, that is noted. Where the evidence is from rodent models only, this site says 'in rodent models' rather than implying human generalizability. Where human data exists (the Tβ4 Phase I trials, the dry eye Phase 2), it is identified as human data and distinguished from the preclinical record. Where no peer-reviewed data exists — as in the TB-500 + BPC-157 combination — this site states that directly. Content is not written by or reviewed by a physician. It is written by editors applying a defined citation protocol to publicly available published science. Questions about medical treatment should be directed to a licensed healthcare provider. Contact: [/contact](/contact). --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor. --- # Contact Doctor TB-500: Editorial Inquiries > Contact the Doctor TB-500 editorial team with research questions, citation corrections, or press inquiries. An independent literature digest — not a clinic, not a vendor. Editorial inquiries about TB-500 and Thymosin Beta-4 research coverage. ## Editorial Inquiries Doctor TB-500 is an independent editorial project summarizing the peer-reviewed research literature on TB-500 and Thymosin Beta-4. We welcome: - **Citation corrections**: If you identify an error in a citation or a misrepresentation of a study's findings, please contact us with the specific study, the error, and the corrected information. We update citations promptly when errors are verified. - **Research questions**: If you have a question about the published literature on TB-500 that is not addressed on this site, we may address it in a future editorial update. - **Press inquiries**: For media inquiries about TB-500 research coverage. We do not provide medical advice. We do not recommend, prescribe, or endorse the use of TB-500 or any research peptide for any purpose. We do not sell any product and are not affiliated with any vendor or supplier. If you have a medical question or health concern, please consult a licensed healthcare provider. Use the form below to reach the editorial team. --- A literature digest of peer-reviewed findings — not a clinic, not a prescription, not a vendor.